The global cell therapy market reached USD 14.52 billion in 2023 and is projected to surpass around USD 97 billion by 2033, poised to grow at a CAGR of 20.9% from 2024 to 2033.
Key Points
- North America led the global market with the highest market share of 53.14% in 2023.
- Asia Pacific region is estimated to expand the fastest CAGR of 16% between 2024 and 2033.
- By user type, the research use segment registered a maximum market share of 62.30% in 2023.
- By user type, the clinical use segment is anticipated to grow at a remarkable CAGR of 13.5% between 2024 and 2033.
- By therapy type, the autologous therapies segment generated over 56% of revenue share in 2023.
The governments all over the world are constantly investing in the biopharmaceutical industry’s development. This has a direct impact on the worldwide cell therapy market’s growth. For the introduction of innovative cell treatments into the worldwide market, leading industry participants are partnering with government authorities.
Get the Sample Pages of Report@ https://www.precedenceresearch.com/sample/1700
Furthermore, for the growth and development of the global cell therapy market, industry participants are focusing on existing and developing areas. The high cost of cell therapies, on the other hand, is a major impediment to the worldwide cell therapy market’s expansion. Furthermore, the cell treatment market’s expansion is hampered by a scarcity of experienced personnel. However, due to the vast range of applications for cell therapy, the worldwide cell therapy market is likely to rise rapidly in the near future.
Regional Snapshot
North America is the largest segment for cell therapy market in terms of region. The U.S. is dominating the cell therapy market in the North America region. For the development of the cell therapy industry, variables such as rising chronic disease occurrences and increasing investments are important. Furthermore, expanding uses of stem cell technology for the treatment of various ailments are propelling the cell therapy market in North America. In addition, the market for cell treatment in North America is rising due to increased research and development activities.
Asia-Pacific region is the fastest growing region in the cell therapy market. China holds the highest market share in the Asia-Pacific cell therapy market. The expansion of the cell therapy market in this region is aided by favorable government policies. In addition, as a result of enhanced healthcare facilities, reduced costs, and rise in awareness of cell therapy, growing nations are expected to rise.
Report Highlights
- On the basis of user type, research use segment holds the largest market share in the global cell therapy market. Cell treatment is commonly employed in scientific studies. The segment’s expansion is being fueled by an increase in research and development projects. Furthermore, important industry participants are heavily spending in research programs. Not only are market participants participating in research projects, but government organizations are also partnering on cell-based research.
- On the basis of therapy type, autologous therapies segment holds the largest market share in the global cell therapy market. The increased usage of autologous therapies on a large scale is credited for the segment’s rise. Furthermore, when compared to allogenic therapies, autologous therapies are very cost effective. As a result, this element is propelling the segment forward.
Cell Therapy Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 20.9% |
| Market Size in 2023 | USD 14.52 Billion |
| Market Size by 2033 | USD 97 Billion |
| North America Market Share in 2023 | 53.14% |
| Research Use Segment Market Share in 2023 | 62.30% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Use Type, By Therapy Type, and By End User |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Cell Therapy Market Dynamics
Drivers
Growing approvals for cell-based therapies
The cell therapies are getting approved easily by government agencies. Since FDA approved products are readily available in developing regions, cell treatments are commonly used. For example, the FDA granted Novartis’ Kymriah regenerative medicine enhanced therapy designation in April 2020 for the treatment of refractory follicular lymphoma in adults. The FDA authorized brexucabtagene autoleucel, a CAR T-cell treatment for patients with mantle cell lymphoma in July 2020.
Restraints
High capital investments for cell therapy plants
People seeking the most up to date alternative remedies for the various ailments have become increasingly interested in stem cell therapy nowadays. Every day, new sorts of therapies are launched and individuals all over the globe are turning to them instead of standard drug regimens and hospital visits. Despite the high demand for stem cell therapies, they are still prohibitively costly to develop. Simple joint injections can set back about $1,000 while more complex procedures can cost up to $100,000 depending on the issue.
Opportunities
Growing government initiatives
The government is heavily investing in research and development activities. The Australian government published The Stem Cell Therapies Mission, journey of 10 years for stem cell research, in November 2019. The Medical Research Future Fund would receive $102 million to support stem cell research in order to develop novel medicines. Thus, the growing government initiatives are creating lucrative opportunities for the growth of global cell therapy market.
Challenges
Lack of skilled professionals
The lack of skilled professionals is a major challenge faced by global cell therapy market. As per the National Accrediting Agency for Clinical Laboratory Sciences, there is a global demand supply mismatch for competent personnel. According to a research study conducted by the Gatsby Foundation, the UK will require an additional 700,000 professionals to sustain the economy by 2030.
Read Also: Protein Ingredients Market Size to Worth US$ 127.50 Bn by 2032
Recent Developments
- Miracell, a Korean stem cell therapy company, will enter the Middle East market in March 2022 after achieving success in Europe. According to the company’s CEO, the afternoons are entirely booked with teleconference with possible Middle Eastern buyers. Miracell is a stem cell therapy and cell banking company that was founded in 2009.
- KIMMTRAK Immunocore’s treatment for advanced and metastatic uveal melanoma was approaved by the FDA in January 2022.
- Thermo Fisher Scientific declared the release of comprehensive and integrated commercial packaging and distribution services in February 2022, designed to help patients across the U.S. and Europe transition from clinic to commercial release. Patheon Commercial Packaging Services is a new end to end solution for programmers that combine worldwide distribution and serialization to assist their logistics strategy.
Cell Therapy Market Companies
- Kolon TissueGene Inc.
- JCR Pharmaceuticals Co. Ltd
- Castle Creek Biosciences Inc.
- Anterogen Co. Ltd
- The Future of Biotechnology
- Celgene Corporation
- Tameika Cell Technologies Inc.
- Cells for Cells
- MEDIPOST
- NuVasive Inc.
Segments Covered in the Report
By Use Type
- Clinical use
- By Therapeutic Area
- Malignancies
- Muscoskeletal Disorders
- Autoimmune Disorders
- Dermatology
- Cardiovascular
- Ocular
- Wounds and injuries
- Others
- By Cell Type
- Stem Cell Therapies
- BM, Blood, & Umbilical cord-derived Stem Cells
- Adipose-derived cells
- Others
- Non-stem Cell Therapies
- By Therapeutic Area
- Research use
By Therapy Type
- Autologous Therapies
- Allogenic Therapies
By End User
- Hospitals
- Diagnostic centers
- Clinics
- Research institutes
- Regenerative medicine centers
- Others
By Technology
- Viral Vector Technology
- Genome Editing Technology
- Somatic Cell Technology
- Cell Immortalization Technology
- Cell Plasticity Technology
- Three-dimensional Technology
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
Blog: https://www.dailytechbulletin.com/
Blog: https://www.autoindustrybulletin.com/